<DOC>
	<DOCNO>NCT01636284</DOCNO>
	<brief_summary>This study determine effectively JX-594 ( Pexa-Vec ) prolong life patient advance Hepatocellular Carcinoma ( HCC ) previously treat sorafenib , safe administration JX-594 five weekly IV infusion .</brief_summary>
	<brief_title>A Phase 2a Study Modified Vaccinia Virus Treat Sorafenib-naïve Advanced Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>KEY Histologic cytologic confirmation advance primary hepatocellular carcinoma ( HCC ) Measurable tumor ( least one tumor ≥1 cm LD contrastenhancement arterial phase CT scanning ) ECOG performance status 0 , 1 2 ChildPugh Class A ; ChildPugh Class B7 without clinically significant ascites Platelet count ≥50,000 plts/mm3 WBC count ≥2,000 cells/mm3 ≤50,000 cells/mm3 Hemoglobin ≥10 g/dL Adequate liver function KEY Received sorafenib previous treatment HCC 14 day History severe exfoliative skin condition ( e.g. , eczema atopic dermatitis require systemic therapy &gt; 4 week ) Prior treatment JX594 Known significant immunodeficiency due underlie illness ( e.g . HIV/AIDS ) and/or medication Severe unstable cardiac disease Viable CNS malignancy associate clinical symptom Pregnant nursing infant Significant bleeding event within last 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Liver Cancer</keyword>
	<keyword>HCC</keyword>
	<keyword>first line HCC</keyword>
	<keyword>Pexa-Vec</keyword>
	<keyword>JX-594</keyword>
</DOC>